Form 4: Apellis Pharmaceuticals Executive Reports Stock Transactions

Mark Jeffrey DeLong, Chief Business & Strategy Officer at Apellis Pharmaceuticals, sold shares to cover tax obligations and received a new restricted stock unit award.

Summary

• Mark Jeffrey DeLong, Chief Business & Strategy Officer of Apellis Pharmaceuticals, sold 1,235 shares of common stock on January 17, 2025, at a price of $29.9582 per share.
• The sale was to cover tax withholding obligations related to restricted stock units.
• On January 21, 2025, Mr. DeLong was granted 28,508 restricted stock units.
• These restricted stock units vest 25% annually over four years from the grant date, contingent upon continued service.

Sentiment

Score: 6

Explanation: The document reflects routine executive stock transactions. The sale is for tax purposes and the grant is part of standard compensation. There is no indication of significant positive or negative sentiment.

Positives

• The grant of 28,508 restricted stock units to the Chief Business & Strategy Officer indicates continued investment in the company's leadership.

Negatives

• The sale of 1,235 shares by the Chief Business & Strategy Officer, while for tax purposes, could be perceived negatively by some investors.

Risks

• Executive stock sales, even for tax purposes, can sometimes be interpreted as a lack of confidence in the company's future performance.

Future Outlook

The restricted stock units will vest over the next four years, subject to continued service.

Management Comments

• The sale of shares was to cover tax withholding on the Restricted Stock Units released on January 16, 2025.
• The Restricted Stock Unit award granted on January 21, 2025 vest 25% annually over four years from grant date subject to continued service.

Industry Context

This is a routine filing related to executive compensation and stock transactions, common in the pharmaceutical industry.

Comparison to Industry Standards

• Stock-based compensation is a common practice in the pharmaceutical industry to incentivize and retain key executives.
• The vesting schedule of 25% annually over four years is a typical vesting structure for restricted stock units.
• Companies like Regeneron Pharmaceuticals (REGN) and Vertex Pharmaceuticals (VRTX) also use similar stock-based compensation plans for their executives.

Stakeholder Impact

• The stock sale may have a minor negative impact on shareholder sentiment, although it is a routine transaction.
• The grant of restricted stock units is a positive for the executive, aligning their interests with the company's long-term performance.

Key Dates

Keywords

Apellis Pharmaceuticals, stock transaction, restricted stock units, executive compensation, insider trading, APLS